Adjusted gross profit for the segment climbed 15.6% to $173.2 million. Nutritional: Perrigo reported revenue of $122 million, down 4.8% year over year. Results were hurt by reduced sales of existing products. Adjusted gross profit for the segment improved 6.2% to $33.2 million in the second quarter of fiscal 2013. The improvement in adjusted gross profit was attributable to a rise in price and a favorable product mix. Rx Pharmaceuticals: The Rx Pharmaceuticals segment performed disappointingly with net sales declining 8.3% to $162.5 million. The decrease was attributable to weak sales of existing products. Increased competition impacted sales of existing products. Adjusted gross profit for the segment decreased 4.9% to $94.5 million. Active Pharmaceutical Ingredients: The company reported API sales of $41 million, down 4% from the prior year quarter. Results were hurt by reduced sales of existing products. Other: Segmental sales declined 5.3% to $18 million.